Arcturus Therapeutics to Release Clinical Data for the Second Stage of Ornithine Transaminase Deficiency and Update mRNA Liver Treatment Platform
2026-09-18 21:01:48
According to CoinMeta, as reported by Reuters, Arcturus Therapeutics will release clinical data from the second phase of studies on ornithine transaminase (Otc) deficiency and provide updates regarding the mRNA liver treatment platform.
Bullish 0
Bearish 0
Source:Internet
This content is for market information only and does not constitute investment advice.